Ulf Persson (Former)
1 – 10 of 51
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
The End of the International Reference Pricing System?
2015) In Applied Health Economics and Health Policy(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
- 2014
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article
-
Mark
Costs and Utilities of Manual Therapy and Orthopedic Standard Care for Low Prioritized Orthopedic Outpatients of Working Age: A Cost Consequence Analysis.
(
- Contribution to journal › Article
-
Mark
Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
(
- Contribution to journal › Article
- 2013
-
Mark
Acute pancreatitis - costs for healthcare and loss of production.
(
- Contribution to journal › Article
- 2012
-
Mark
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
(
- Contribution to journal › Article